TrkB, a potent anoikis suppressor, is overexpressed in several kinds of malignancies, and BDNF-mediated activation of TrkB (ligand binding to the receptor) contributes to anoikis resistance of cancer cells, including HCC [36]. This evidence concerns the gene NTRK2 and cancer.